FARMINGDALE, N.Y., April 2, 2013 /PRNewswire/ -- Misonix, Inc. (NasdaqGM: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, has entered into a new, three year, exclusive distribution agreement with Maersk-Andersen AS, based in Randers, Denmark, for the distribution of the Misonix® BoneScalpel™ Ultrasonic Bone Cutting System. The agreement provides Maersk-Andersen with the right to sell throughout Denmark. Included in the agreement are annual minimum purchase requirements. Product training has been completed and open market sales have commenced.
Maersk-Andersen, known for their focused market presence in neuro, spine and other orthopedic surgeries, is well prepared and strategically well positioned to successfully introduce high tech products, like the BoneScalpel, to the Danish market. Their commitment to clinical education and product service is well known and separates them from the competition.
The Misonix BoneScalpel is a novel ultrasonic osteotome (bone cutting device) used for safe, tissue-selective bone dissection that encourages non-fragmented bone removal and refined osteotomies while sparing elastic soft tissue structures. Most users report that the surgical field is relatively clean and bloodless. Loss of viable bone is minimal and controllable. The BoneScalpel has been used extensively for bone removal in spine surgery and maxillo-facial reconstructive surgery.
"It is our pleasure to add Maersk-Andersen to our distribution organization in Europe; their presence in a sophisticated healthcare market like Denmark could add measurably to our sales success. Their history of successfully introducing cutting edge products to the Danish market is well known to us," said Michael A. McManus, Jr. , President and Chief Executive Officer of Misonix.
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.Investor Relations ContactsMisonix Contact:
Lytham Partners, LLCRichard Zaremba
Robert Blum, Joe Dorame, Joe Diaz631-694-9555
|SOURCE Misonix, Inc.|
Copyright©2012 PR Newswire.
All rights reserved